The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy

Colorectal cancer (CRC) is considered one of the leading types in world. CD133, as a stem cell marker, has pivotal role development drug resistance, migration, and stemness properties CRC cells. This study was designed to check combined effect CD133 siRNA Oxaliplatin on proliferation, apoptosis, cells HT-29 line. MTT assay performed define viability cells, it showed that combination could reduce IC50 this from 32.85 19.75 nmol. In order figure out therapy expression at gene protein level, qRT-PCR western blot were exploited, respectively. The results demonstrated silencing relative marker about 0.00001 compared control group level 0.01. ability migration tested by wound healing well. Also, colony formation sphere conducted assess group. Flow cytometry investigate apoptosis (15%), cycle (about 10% arresting G0-G1 phase), surface different groups (from 39.3% 2.41 group). Finally, migration-, stemness-associated genes measured qRT-PCR. We indicated reduces colorectal cancerous suppression makes more sensitive effective dose chemical drug. Therefore, with treatment might be promising therapeutic approach cancer.